The Participation Of Prolactin In The Immunopathology Of Experimental Pulmonary Tuberculosis.

The Participation Of Prolactin In The Immunopathology Of Experimental Pulmonary Tuberculosis.

Publication date: May 28, 2026

Prolactin and its receptor are widely recognized for their roles in lactogenesis and galactopoiesis. However, they have also gained attention for their role in immune pathophysiology, acting as mediators of both innate and acquired immune responses and potentially playing a significant role in chronic infectious diseases such as tuberculosis. In this study, we examined the kinetics of prolactin and its receptor during the progression of experimental pulmonary tuberculosis in BALB/c mice infected intratracheally with a high-dose Mycobacterium tuberculosis (M. tuberculosis) reference strain, H37Rv. Groups of infected mice were euthanized at various time points, and their lungs were collected to quantify gene expression of prolactin and its receptor by RT-PCR, as well as to assess cellular expression by immunohistochemistry. In vitro infection experiments with alveolar macrophages and type II pneumocyte cell lines were conducted to evaluate the effects of prolactin on bacteriolysis and the expression of various innate immune response factors. After two months of infection, BALB/c mice with progressive pulmonary tuberculosis were treated with ovine PRL, and the effects were assessed by measuring bacillary loads and the extent of tissue damage (pneumonia). In vitro studies showed that prolactin increases bacterial phagocytosis in alveolar macrophages and significantly enhances the production of reactive oxygen and nitrogen species, which reduces bacillary loads. In type II pneumocytes, prolactin, under certain conditions, induces higher, though not statistically significant, expression of cathelicidin and surfactant proteins A and D. In vivo studies revealed that, during early infection (within the first week), there was high expression of prolactin and its receptor in the lungs. Immunostaining for prolactin and its receptor was observed at the early stage of infection, mainly in alveolar epithelial cells, macrophages, and lymphocytes. During the second week of infection, immunostaining showed the organization of macrophages and lymphocytes within granulomas and in the inflammatory infiltrate around blood vessels and airways, with macrophages showing the strongest staining. Over the course of progressive disease, after one month of infection, pulmonary prolactin production decreased, and some macrophages and lymphocytes showed minimal prolactin immunostaining, although high prolactin receptor expression persisted; four months later, prolactin immunostaining was observed in the bronchial epithelium. Administration of prolactin via intraperitoneal injection two months after infection resulted in a significant reduction in bacillary loads after two months of treatment, along with increased but not statistically significant expression of TNFα and IFNγ. Prolactin and its receptors appear to contribute to immune activation during pulmonary tuberculosis, particularly in the early stages of infection. Prolactin administration during late active disease reactivates immune protection. Although we do not demonstrate the mechanisms underlying these observations, these results could serve as a basis for expanding future experimental research.

Open Access PDF

Concepts Keywords
Euthanized Alveolar
Immunohistochemistry Bacillary
Infectious Experimental
Pneumonia Expression
Week High
Immune
Immunostaining
Infection
Macrophages
Months
Prolactin
Pulmonary
Receptor
Significant
Tuberculosis

Semantics

Type Source Name
disease MESH Pulmonary Tuberculosis
disease MESH infectious diseases
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH strain
disease MESH infection
disease MESH pneumonia
drug DRUGBANK Oxygen
drug DRUGBANK Nitrogen
disease MESH granulomas
drug DRUGBANK Coenzyme M
disease MESH injury
pathway REACTOME Metabolism
disease MESH inflammation
drug DRUGBANK Somatotropin
drug DRUGBANK Nitric Oxide
disease MESH death
disease MESH hyperprolactinemia
drug DRUGBANK Oleic Acid
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Phosphate ion
disease MESH PBS
drug DRUGBANK Sevoflurane
drug DRUGBANK Pentobarbital
drug DRUGBANK Ethanol
drug DRUGBANK Collagenase clostridium histolyticum
disease MESH included
drug DRUGBANK Water
drug DRUGBANK Abacavir
drug DRUGBANK Cefaclor
disease MESH CCL
drug DRUGBANK Methylergometrine
disease MESH FBS
pathway REACTOME Antimicrobial peptides
disease MESH autoimmune diseases
disease MESH bacterial infections
pathway REACTOME Immune System
disease MESH LPS
disease MESH pulmonary disease
drug DRUGBANK Fenamole
disease MESH mend
pathway REACTOME Prolactin receptor signaling
disease MESH Dis
pathway REACTOME Apoptosis
drug DRUGBANK Copper
drug DRUGBANK Mannose
drug DRUGBANK Diethylstilbestrol
disease MESH Des
disease MESH MHS

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *